Announcements Trials
Browse Landscape

Status

Recruiting 3Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 52Observational 6Expanded_access 1

Sponsor

Cancer Type

Breast 6

Conditions

Breast Neoplasms 6

Interventions

Surveys and Questionnaires 53Blood Specimen Collection 53Specimen Handling 28Radiotherapy 18Observation 18Interviews as Topic 13Magnetic Resonance Spectroscopy 12Surgical Procedures, Operative 10Drug Therapy 10Data Collection 10Biopsy 10Tomography, X-Ray Computed 9darolutamide 8Watchful Waiting 7Standard of Care 7ribociclib 6palbociclib 6Restraint, Physical 6Patient Reported Outcome Measures 6Magnetic Resonance Imaging 6Immune Checkpoint Inhibitors 6trastuzumab deruxtecan 5Positron-Emission Tomography 5Mass Screening 5Genetic Testing 5Esophagectomy 5Breath Tests 5Bevacizumab 5enzalutamide 4apalutamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Observational × ribociclib × 90 days × Clear all
NCT06930859 2026-05-22

ELEGANCE

Novartis

Recruiting
2,766 enrolled
Breast

Breast Neoplasms

NCT06830720 2026-05-08

CAROLEEN

Novartis

Recruiting
3,250 enrolled
Breast

Breast Neoplasms

NCT06075758 2026-05-06

A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer

Novartis

Completed
175 enrolled
Breast

Breast Neoplasms

NCT06905301 2026-05-05

IMPULSE

Novartis

Recruiting
240 enrolled
Breast

Breast Neoplasms

NCT04943497 2026-04-01

PROSPERITY

Novartis

Completed
2,424 enrolled
Breast

Breast Neoplasms

NCT05697146 2026-03-16

RosaLEE

Novartis

Active not recruiting
1,019 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡